Abstract
The liver is the most common anatomical site for hematogenous metastases of colorectal cancer, and colorectal liver metastases is one of the most difficult and challenging points in the treatment of colorectal cancer. To improve the diagnosis and comprehensive treatment in China, the Guidelines have been edited and revised several times since 2008, including the overall evaluation, personalized treatment goals and comprehensive treatments, to prevent the occurrence of liver metastases, improve the resection rate of liver metastases and survival. The revised Guideline includes the diagnosis and follow-up, prevention, MDT effect, surgery and local ablative treatment, neoadjuvant and adjuvant therapy, and comprehensive treatment, and with advanced experience, latest results, detailed content, and strong operability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adam R et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treatm Rev 41:729–741. https://doi.org/10.1016/j.ctrv.2015.06.006
Andre T et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. https://doi.org/10.1200/JCO.2008.20.6771
Antoniou A et al (2007) Meta-analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery 141:9–18. https://doi.org/10.1016/j.surg.2006.07.045
Begin A et al (2014) Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP). Surg Endosc 28:3408–3412. https://doi.org/10.1007/s00464-014-3611-x
Bertens KA, Hawel J, Lung K, Buac S, Pineda-Solis K, Hernandez-Alejandro R (2015) ALPPS: challenging the concept of unresectability—a systematic review. Int J Surg 13:280–287. https://doi.org/10.1016/j.ijsu.2014.12.008
Brouquet A, Andreou A, Vauthey JN (2011) The management of solitary colorectal liver metastases. Surgeon 9:265–272. https://doi.org/10.1016/j.surge.2010.12.005
Cervantes A, Rosello S, Rodriguez-Braun E, Navarro S, Campos S, Hernandez A, Garcia-Granero E (2008) Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol 19(Suppl 7):vii266–vii272. https://doi.org/10.1093/annonc/mdn438
Chang W et al (2016) Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer. Ann Surg 263:434–439. https://doi.org/10.1097/SLA.0000000000001374
Chau I, Chan S, Cunningham D (2003) Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin Colorectal Cancer 3:19–33. https://doi.org/10.3816/CCC.2003.n.009
Coenegrachts K, De Geeter F, ter Beek L, Walgraeve N, Bipat S, Stoker J, Rigauts H (2009) Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 19:370–379. https://doi.org/10.1007/s00330-008-1163-y
de Jong MC et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250:440–448. https://doi.org/10.1097/SLA.0b013e3181b4539b
Delbeke D, Martin WH (2004) PET and PET–CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209–223
Esin E, Yalcin S (2016) Maintenance strategy in metastatic colorectal cancer: a systematic review. Cancer Treat Rev 42:82–90. https://doi.org/10.1016/j.ctrv.2015.10.012
Falcone A et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676. https://doi.org/10.1200/JCO.2006.09.0928
Folprecht G et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47. https://doi.org/10.1016/S1470-2045(09)70330-4
Foster JH (1984) Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis 4:170–179. https://doi.org/10.1055/s-2008-1040656
Fraker DL, Soulen M (2002) Regional therapy of hepatic metastases. Hematol Oncol Clin N Am 16:947–967
Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/S0140-6736(12)61900-X
Hur H et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736. https://doi.org/10.1016/j.amjsurg.2008.04.013
Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. https://doi.org/10.1056/NEJMoa032691
Iwamoto S et al (2014) Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 34:1967–1973
Jones OM, Rees M, John TG, Bygrave S, Plant G (2005) Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 92:1165–1168. https://doi.org/10.1002/bjs.4888
Kawaguchi Y et al (2014) Surgical resection for local recurrence after radiofrequency ablation for colorectal liver metastasis is more extensive than primary resection. Scand J Gastroenterol 49:569–575. https://doi.org/10.3109/00365521.2014.893013
Kemeny N et al (2005) Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888–4896. https://doi.org/10.1200/JCO.2005.07.100
Koshariya M et al (2007) An update and our experience with metastatic liver disease. Hepatogastroenterology 54:2232–2239
Li J et al (2018) Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA J Am Med Assoc 319:2486–2496. https://doi.org/10.1001/jama.2018.7855
Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver. metastases. Radiology 266:407–430. https://doi.org/10.1148/radiol.12112544
Mohiuddin M, Chen E, Ahmad N (1996) Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 14:722–728. https://doi.org/10.1200/JCO.1996.14.3.722
Nordlinger B, Vauthey JN, Poston G, Benoist S, Rougier P, Van Cutsem E (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9:212–218. https://doi.org/10.3816/CCC.2010.n.031
Nosher JL, Ahmed I, Patel AN, Gendel V, Murillo PG, Moss R, Jabbour SK (2015) Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol 6:224–240. https://doi.org/10.3978/j.issn.2078-6891.2014.065
Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033–1038. https://doi.org/10.1038/sj.bjc.6605259
Okuno K (2007) Surgical treatment for digestive cancer. Current issues—colon cancer. Dig Surg 24:108–114. https://doi.org/10.1159/000101897
Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860–868. https://doi.org/10.1007/s11605-007-0149-4
Poultsides GA et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384. https://doi.org/10.1200/JCO.2008.20.9817
Primrose J et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:601–611. https://doi.org/10.1016/S1470-2045(14)70105-6
Ratti F et al (2015) Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy. Ann Surg Oncol 22:1933–1942. https://doi.org/10.1245/s10434-014-4291-4
Rex DK et al (2006) Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer CA: a cancer. J Clin 56:160–167 (quiz 185–166)
Roxburgh CS, Richards CH, Moug SJ, Foulis AK, McMillan DC, Horgan PG (2012) Determinants of short- and long-term outcome in patients undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases. Int J Colorectal Dis 27:363–369. https://doi.org/10.1007/s00384-011-1339-9
Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578. https://doi.org/10.1200/JCO.2008.19.6329
Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D (2009) Local surgical, ablative, and radiation treatment of metastases CA: a cancer. J Clin 59:145–170. https://doi.org/10.3322/caac.20013
Tomlinson JS et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580. https://doi.org/10.1200/JCO.2007.11.0833
Topkan E, Onal HC, Yavuz MN (2008) Managing liver metastases with conformal radiation therapy. J Support Oncol 6:9–13, 15
Torres OJ, Moraes-Junior JM, Lima e Lima NC, Moraes AM (2012) Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new approach in liver resections. Braz Arch Dig Surg 25:290–292
Van Cutsem E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. https://doi.org/10.1056/NEJMoa0805019
Van Cutsem E et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:692–700. https://doi.org/10.1200/JCO.2014.59.4812
Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D (2003) Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 90:956–962. https://doi.org/10.1002/bjs.4132
Wolpin BM, Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134:1296–1310. https://doi.org/10.1053/j.gastro.2008.02.098
Xu J et al (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245:583–590. https://doi.org/10.1097/01.sla.0000250453.34507.d3
Xu RH et al (2018) Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19:660–671. https://doi.org/10.1016/s1470-2045(18)30140-2
Acknowledgements
The members of China CRLM Guideline Group are Yi Ba, Jianhong Bu, Jianhui Cai, Sanjun Cai, Shan Zeng, Zhaochong Zeng, Gong Chen, Yu Chen, Zihua Chen, Zongyou Chen, Jiemin Cheng, Pan Chi, Guanghai Dai, Yong Dai, Yanhong Deng, Kefeng Ding, Xuedong Fang, Chuangang Fu, Jianping Gong, Chunyi Hao, Yulong He, Zhongcheng Huang, Jiafu Ji, Baoqing Jia, Kewei Jiang, Jing Jin, Dalu Kong, Ping Lan, Dechuan Li, Guoli Li, Jin Li, Leping Li, Yunfeng Li, Zhixia Li, Houjie Liang, Xiaobo Liang, Feng Lin, Jianjiang Lin, Hongjun Liu, Tianshu Liu, Yunpeng Liu, Hongming Pan, Zhizhong Pan, Haiping Pei, Tao Peng, Li Ren, Lin Shen, Chun Song, Tianqiang Song, Xiangqian Su, Yihong Sun, Min Tao, Liguo Tian, Desen Wan, Jianping Wang, Guiying Wang, Guiyu Wang, Haijiang Wang, Jianhua Wang, Lei Wang, Xin Wang, Yajie Wang, Yi Wang, Ziqiang Wang, Ye Wei, Dong Wei, Feng Xia, Jianguo Xia, Lijian Xia, Baocai Xing, Bin Xiong, Jianming Xu, Nong Xu, Ruihua Xu, Ye Xu, Zekuan Xu, Zhongfa Xu, Shujun Yang, Hongwei Yao, Yingjiang Ye, Peiwu Yu, Ying Yuan, Jun Zhang, Keliang Zhang, Wei Zhang, Xiaotian Zhang, Yanqiao Zhang, Youcheng Zhang, Zhen Zhang, Qingchuan Zhao, Ren Zhao, Shu Zheng, Aiping Zhou, Jian Zhou, Zongguang Zhou.
Funding
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The author(s) declare that they have no competing interests.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
The members of China CRLM Guideline Group are listed to Acknowledgements section.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Xu, J., Fan, J., Qin, X. et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol 145, 725–736 (2019). https://doi.org/10.1007/s00432-018-2795-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-018-2795-1